Changes in brain vMRI (ml, %) detected by boundary shift integral (BSI) 42 , an analytic method employed in other HD studies 21 – 23 , 43 , showed a nominally significant 26% reduction in caudate atrophy for EM subjects (PEPI, n = 90; PBO, n = 88) treated with pepinemab relative to placebo, and the percentage change from baseline at month 17 resulted in LS mean difference (95% CI) = −1.54 (−2.79, −0.29) (two-sided P = 0.017; Fig. 2a and Extended Data Table 4 ).
← all excerpts
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
1
—
—